Changes in prescribing rates of sodium-containing medications in the UK from 2009 to 2018:a cross-sectional study with interrupted time series analysis by Ju, Chengsheng et al.
                                                                    
University of Dundee
Changes in prescribing rates of sodium-containing medications in the UK from 2009 to
2018








Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Ju, C., Wei, L., Mackenzie, I. S., MacDonald, T. M., & George, J. (2021). Changes in prescribing rates of
sodium-containing medications in the UK from 2009 to 2018: a cross-sectional study with interrupted time series
analysis. BMJ Open, 11(2), [e043566]. https://doi.org/10.1136/bmjopen-2020-043566
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 20. Apr. 2021
1Ju C, et al. BMJ Open 2021;11:e043566. doi:10.1136/bmjopen-2020-043566
Open access 
Changes in prescribing rates of sodium- 
containing medications in the UK from 
2009 to 2018: a cross- sectional study with 
interrupted time series analysis
Chengsheng Ju   ,1 Li Wei   ,1 Isla S Mackenzie   ,2 Thomas M MacDonald   ,2 
Jacob George   2
To cite: Ju C, Wei L, 
Mackenzie IS, et al.  Changes 
in prescribing rates of sodium- 
containing medications in the 
UK from 2009 to 2018: a cross- 
sectional study with interrupted 
time series analysis. BMJ Open 
2021;11:e043566. doi:10.1136/
bmjopen-2020-043566
 ► Prepublication history and 
additional materials for this 
paper is available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2020- 
043566).
Received 07 August 2020
Revised 23 January 2021
Accepted 30 January 2021
1Research Department of 
Practice and Policy, School of 
Pharmacy, University College 
London, London, UK
2Molecular and Clinical 
Medicine, University of Dundee, 
Dundee, UK
Correspondence to
Professor Li Wei;  
 l. wei@ ucl. ac. uk
Original research
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Objective Effervescent, soluble, dispersible 
formulations contain considerable amounts of sodium. In 
2013, we previously confirmed the association between 
sodium- containing medications and cardiovascular 
risks. This study aimed to determine the changes in the 
prescribing pattern in clinical practice following this 
publication.
Design A longitudinal cross- sectional study.
Setting Primary care in the UK from 2009 to 2018.
Participants Prescribing information in The Health 
Improvement Network (THIN) and Prescription Cost 
Analysis (PCA) databases in the UK.
Outcome measurements Prescription rates per 
10 000 inhabitants were calculated using the number of 
prescriptions or the number of drug- using patients over 
the total number of inhabitants, and the prescription rates 
were measured at annual intervals. Prescribing trends 
from 2009 to 2018 were indexed with yearly data from 
THIN and PCA. Interrupted time series analysis (ITSA) was 
conducted with monthly data in THIN.
Results From the THIN database, a total of 3 651 419 
prescription records from 446 233 patients were included. 
The prescribing rate of sodium- containing medications 
changed from 848.3/10 000 inhabitants in 2009 to 
571.6/10 000 inhabitants in 2018. The corresponding 
figures from PCA data were of 631.0/10 000 inhabitants 
in 2009 and 423.8/10 000 inhabitants in 2018. ITSA 
showed the prescribing trend reduced significantly 
during the postpublication period (prescribing rate: 
slope change=−0.26; 95% CI −0.45 to –0.07; p=0.009; 
proportion of patients: slope change=−0.22; 95% CI −0.35 
to –0.09; p<0.001), but no change in postpublication level 
from baseline. The prescribing rates for the non- sodium- 
containing standard formulations were relatively stable 
over the study period. The reduction in the proportion of 
patients using sodium- containing medications was only 
significant in patients over 45 years old.
Conclusions The prescribing of sodium- containing 
medications in the UK primary care has declined 
significantly during the postpublication period. Changes 
in the prescribing trends for sodium- containing 
medications varied across regions of the UK and patient 
age groups.
INTRODUCTION
There is little doubt that excess dietary salt 
is a major public health problem. High salt 
intake has been emphasised as a major cardio-
vascular risk factor.1 2 In 2010, it was estimated 
that 1.65 million cardiovascular deaths were 
attributed to high sodium salt consumption.3 
The UK Food Standards Agency campaign 
was launched in 2004 to try to reduce salt 
intake in the estimated 26 million people in 
the UK who have high dietary salt.4 Reducing 
salt intake would very significantly reduce 
the multiple adverse effects on health5 such 
as hypertension, which leads to substantial 
economic benefits.6 While a very consid-
erable effort is being made to reduce salt 
intake in the population in general, we are 
concerned that a significant sodium salt load 
is being ingested via certain medications. The 
recommended sodium intake for an adult 
is between 50 and 65 mmol/day. However, 
dispersible paracetamol can contain up 
to 18.6 mmol of sodium and effervescent 
preparations can contain up to 16.9 mmol 
of sodium per 500 mg tablet. Therefore, the 
maximum daily dose of 4000 mg/day or eight 
tablets will result in ingestion of twice the 
recommended daily allowance of sodium in 
one medication alone. Despite this fact, the 
Strengths and limitations of this study
 ► This was the first study examining changes in the 
prescribing of sodium- containing formulations in 
the UK.
 ► This study involved a large number of prescription 
records and patient records from two large databas-
es in the UK.
 ► We did not investigate comorbidities associated with 
discontinuation of sodium- containing medications.
 ► The effects of potential other factors cannot be ruled 
out.
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cardiovascular impact of these sodium- containing medi-
cations has long been neglected.
In November 2013, we published a UK database study in 
the BMJ on the association of sodium- containing efferves-
cent medications on long- term cardiovascular risks.7 We 
found that exposure to these medications was associated 
with a sevenfold increased risk of hypertension and a 16% 
higher risk for subsequent cardiovascular events. The 
results were later confirmed by a randomised, crossover 
trial evaluating the effect of effervescent paracetamol on 
blood pressure8 and a meta- analysis of eight studies.9 In 
2015, the Pharmacovigilance Risk Assessment Committee 
of the European Medicines Agency (EMA) adopted the 
findings and have suggested labelling changes to these 
high sodium- containing medications. With regard to the 
use of sodium- containing medications, to date, there is 
only one recent French study that evaluated factors asso-
ciated with exposure to effervescent drugs,10 while there 
is no updated information on prescribing patterns of 
sodium- containing medicines following the BMJ publica-
tion and EMA guideline changes. Given the detrimental 
health effects of excess sodium consumption by intake of 
the high sodium- containing medications, it is therefore 
important to evaluate the impact of the evidence change 
on the real- world practice of sodium- containing medica-
tion prescribing.
The aim of this study was to investigate prescribing 
patterns of effervescent, soluble and dispersible medica-
tions in the UK following the publication in November 
2013 of discovery of an association with increased cardio-
vascular risk in patients prescribed these medications 
long term.
METHODS
Study design and data source
This was a longitudinal study using The Health Improve-
ment Network (THIN) database and Prescription Cost 
Analysis (PCA) database for the period between 1 January 
2009 and 31 December 2018, which were 5 years before 
and after the original 2013 publication.
THIN is a nationwide database of primary care records 
in the UK that contains around 6% of the total UK popu-
lation. IQVIA Medical Research Data UK incorporating 
THIN, THIN is a registered trademark of Cegedim SA 
in the UK and other countries. Reference made to the 
THIN database is intended to be descriptive of the data 
asset licensed by IQVIA. This work uses de- identified data 
provided by patients as a part of their routine primary 
care. Previous studies have demonstrated the validity of 
THIN database for pharmacoepidemiological studies and 
its generalisability to the UK population.11 12 The PCA is a 
publicly published database containing yearly prescribing 
data for all prescriptions dispensed in the community 
by general practitioners, community pharmacists and 
appliance contractors. Separate PCA databases exist for 
the prescribing data in England, Scotland and Wales. 
The data were published by the National Health Service 
(NHS) England, Public Health Scotland and NHS Wales, 
respectively. Prescriptions dispensed in hospitals or the 
private sector are not captured. Data in the PCA data-
bases have been proven to reach a level of accuracy of 
98%–99% and have been used for producing high quality 
research in pharmacoepidemiological studies from local 
research teams.13 14
Drug treatment
In the original 2013 BMJ publication, we previously 
identified 38 different preparations that are available 
on prescription as both effervescent or dispersible 
containing sodium and have had more than 1000 therapy 
events in Clinical Practice Research Datalink database.7 
The same preparations were mapped in the PCA database 
and THIN database and were used as the study prepara-
tions in this follow- on study. Details of the preparations 
and classifications were included in online supplemental 
table S1 for the PCA database and online supplemental 
table S2 for the THIN database.
Study outcome
The primary outcome of this study was the prescribing 
trends of sodium- containing medications. Using the 
THIN data which contains patient- level data, we measured 
the prescribing trends by annual prescription rate per 
10 000 inhabitants, which were calculated as the number 
of sodium- containing medication prescriptions in a 
particular year divided by the corresponding yearly active 
population in THIN. We also measured the trends by 
yearly proportions of medication users per 10 000 inhab-
itants, which were calculated as the number of patients 
who received a prescription of the study medications in a 
particular year divided by the corresponding yearly active 
population in THIN at each measurement. The number 
of active mid- year population in THIN was provided by 
the THIN database by summarising the demographic 
information for all patients included in the database. 
We excluded records of patients who received their first 
prescription of sodium- containing medication before the 
age of 18 years. We also examined the effect of demo-
graphic factors, that is, age and sex, on the prescribing 
of sodium- containing. We stratified the medication users 
according to sex (male or female) and age groups (<45 
years, 45–54 years, 55–64 years, 65–74 years, 75–85 years 
or ≥85 years).
To increase the robustness of our findings, we also 
indexed the prescribing trends by calculating the yearly 
prescription rates from the PCA database using the 
number of prescriptions divided by the estimated mid- year 
population of the same year for each region. Estimated 
mid- year population data was obtained from Office for 
National Statistics from 2009 to 2018 for England, Scot-
land and Wales on a yearly basis. In order to assess the 
regional variation in the impact of the 2013 publication, 
data in England, Scotland and Wales were analysed sepa-
rately alongside the total data from these three regions.
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Statistical analysis
We first described long- term prescribing trends on the 
prescribing of sodium- containing medications from 2009 
to 2018. We indexed the descriptive time series with yearly 
prescribing data from THIN and PCA databases, respec-
tively. We also collated data on non- sodium- containing 
standard formulations, which are comparable to the study 
medications. The prescribing of sodium- containing medica-
tions was compared with that of the standard non- sodium- 
containing preparations.
To evaluate the impact of the publication on the 
prescribing of sodium- containing medications, we 
conducted the interrupted time series analysis (ITSA) using 
monthly prescribing data from the THIN database between 
2012 and 2015. A shorter time frame was used for ITSA to 
avoid including effect of other intervention or evidence 
change during the study period. We used segmented linear 
regression models to examine changes in prescribing 
rates and proportions of sodium- containing medication 
users after the BMJ publication. The model both estimates 
the preintervention level and slope as well as controls the 
baseline level and slope of the time series to estimate the 
changes in level and slope after the intervention. The level 
change evaluates the immediate effect of the publication, 
and the slope change represents the gradual effect over 
time. The prescribing of standard non- sodium- containing 
formulations was used as the control series, and we repeated 
ITSA on the prescribing rates and proportion of patients to 
compare with the results of the sodium- containing medi-
cations. Autocorrelation of the times series was tested with 
Durbin- Watson statistic and corrected where appropriate. 
Seasonality was adjusted where appropriate. The interven-
tion time was set as January 2014, with 2- month lag time 
from the publication in November 2013. There were 24 data 
points before and after the intervention. We analysed the 
prescribing of medications of each therapeutic class sepa-
rately, where there were more than 100 observations at each 
measurement. We also analysed changes in the proportion 
of medication users in each sex and age group. A two- sided 
α of less than 0.05 was considered statistically significant. All 
analyses were conducted using SAS V.9.4 (SAS Institute).
Sensitivity analyses
We conducted two sensitivity analyses. First, we changed 
the time frame for the ITSA. We repeated the analysis with 
30 months preintervention/postintervention, rather than 
24 months. Second, we changed the intervention time to 
January 2016 and compared the prescribing trends 2014–
2015 versus 2016–2017, when the EMA published the revi-
sion on the guidelines of excipient labelling, to assess the 
additive effects on prescribing rate.
RESULTS
Prescribing trends from 2009 to 2018
From the THIN database, we identified 3 922 400 prescrip-
tion records of sodium- containing preparations from 
579 746 patients. Of these patients, 8620 patients with 
substandard records with data integrity issues defined 
by THIN were excluded. A total of 123 893 patients who 
received their first prescription of the sodium- containing 
medication before the age of 18 years were further 
excluded. Finally, 3 651 419 prescription records from 
446 233 patients were included in the analyses.
The annual prescribing of sodium- containing medi-
cations reduced markedly from 2009 to 2018. The 
prescribing rate decreased from 848.3 prescriptions 
per 10 000 inhabitants in 2009 to 792.5 prescriptions 
per 10 000 inhabitants in 2013 (6.6% reduction) and 
to 571.6 prescriptions per 10 000 inhabitants in 2018 
(27.9% reduction). Most reductions occurred after 2013 
(figure 1A). The trend for the prescribing of control 
drugs (non- sodium- containing standard formulations) 
was different. The prescribing rates increased from 7792.8 
prescriptions per 10 000 inhabitants in 2009 to 9018.0 
prescriptions per 10 000 inhabitants in 2013 (13.6% 
increase). There was a plateau from 2013 to 2018, with a 
reading of 8954.6 prescriptions per 10 000 inhabitants in 
2018 (figure 1B). The same pattern was observed when 
the trend was measured in the proportion of medication 
users. There was a minor decrease from 249.3 patients 
per 10 000 inhabitants in 2009 to 240.2 prescriptions per 
10 000 inhabitants in 2013 (3.7%), and then reduced 
substantially to 169.9 patients per 10 000 inhabitants in 
2018 (29.3%) (figure 1C). Similarly, when the trend for 
control formulations was measured in the proportion of 
patients, little change occurred from 2009 to 2018. The 
proportion of medication user was 1475.6, 1542.7 and 
1417.3 patients per 10 000 inhabitants in 2009, 2013 and 
2018, respectively (figure 1D). The trends of prescribing 
measured by the proportion of patients stratified by 
sex were presented in figure 2A and by age group in 
figure 2B.
We extracted 35 069 427 prescription records of 
sodium- containing medications, of which 29 964 749 
were in England, 3 488 523 in Scotland and 1 616 155 in 
Wales. The trends derived from PCA data were similar 
to the trends from THIN data. The prescribing rate of 
sodium- containing medications changed from 631.0 
prescription per 10 000 inhabitants in 2009 to 612.1 
prescription per 10 000 inhabitants in 2013 (3.0% reduc-
tion), and 423.8 prescription per 10 000 inhabitants in 
2018 (30.8% reduction) (figure 3A). The measurements 
for non- sodium- containing formulations were 8759.7 in 
2009, 10 306.3 in 2013 and 9833.5 in 2018 (figure 3B). 
When stratified by regions, the results were presented 
in figure 3C for sodium- containing formulations and 
figure 3D for non- sodium- containing standard formula-
tions. The trends in England and Scotland were similar 
to THIN data (England: 615.0 in 2009, 603.3 in 2013 and 
413.6 in 2018; Scotland: 732.5 in 2009, 708.9 in 2013 and 
501.5 in 2018), while in Wales, the prescribing decreased 
steadily over the period (623.4 in 2009 to 531.4 in 2013, 
and to 414.8 in 2018). For the control series of standard 
formulations, the trends were similar across all three 
regions.
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ITSA of 2012–2013 versus 2014–2015: impact of the BMJ 
publication
The monthly prescribing rate of sodium- containing 
formulations did not change during the 2- year period 
before the publication (baseline slope estimate=0.03; 
95% CI −0.13 to 0.18). After the publication, the slope 
reduced significantly by 0.26 per month (95% CI −0.45 
to –0.07; p=0.009). No change in postpublication level 
was observed (level change=0.59; 95% CI −2.19 to 3.37; 
p=0.678). While for the control series of the prescribing 
of non- sodium standard formulations, there was no 
change in either slope or level post publication (slope 
change=1.14; 95% CI −0.99 to 3.27; p=0.294; level 
change=22.3; 95% CI −8.14 to 52.7; p=0.151). When we 
stratify the prescriptions by the therapeutic classes, the 
significantly decreased slopes were observed for calcium 
supplements (slope change=−0.03; 95% CI −0.06 to –0.01; 
p=0.014), gastrointestinal (GI) motility agents (slope 
change=−0.17; 95% CI −0.24 to –0.09; p<0.001) and corti-
costeroids (slope change=−0.03; 95% CI −0.05 to –0.02; 
p<0.001), while the slope did not change significantly 
for analgesics (slope change=−0.03; 95% CI −0.10 to 0.05; 
p=0.510), as there was a decreasing slope for analgesic 
prepublication (slope estimate=−0.11; 95% CI −0.17 to 
–0.05). There was no change in level for any class of medi-
cations (table 1).
The time series measured by the proportion of sodium- 
medication users were consistent with the prescribing 
rates measured by the number of prescriptions. There 
was no difference in trends between men and women, 
although the baseline level for women (73.38 monthly; 
95% CI 70.51 to 76.25) was twofold higher than men 
(39.10 monthly; 95% CI 37.61 to 40.59). The trends were 
also largely consistent across age groups. Significant 
reductions in monthly prescribing postpublication were 
observed for all age groups, except for patients under 45 
years (slope change=−0.32; 95% CI −0.07 to 0.01; p=0.113) 
(table 1).
When the ITSA was repeated with 30 months before 
and after the publication, similar results were obtained 
(online supplemental table S3).
Figure 1 Prescribing trends of sodium- containing medications and control medications from 2009 to 2018, The Health 
Improvement Network data; (A) sodium, prescribing rate; (B) control, prescribing rate; (C) sodium, proportion of patients; and (D) 
control, proportion of patients.
Figure 2 Prescribing trends of sodium- containing medications measured by the proportion of patients from 2009 to 2018, The 
Health Improvement Network data; (A) by sex and (B) by age group.
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Changes in prescribing trends after the EMA guideline change 
in 2015
To assess the impact of the EMA guideline revision in 
2015 on the prescribing of sodium- containing medica-
tions, the monthly prescribing from 2014–2015 versus 
2016–2017 was compared with ITSA. Significant reduc-
tions were observed for both sodium- containing medi-
cations (prescribing rate: slope change=−0.24; 95% CI 
−0.41 to –0.06; p=0.007; proportion of patients: slope 
change=−0.19; 95% CI −0.29 to –0.08; p=0.001) and also 
for non- sodium control formulations. There was a signif-
icant reduction in level when the prescribing of sodium- 
containing medications was measured in the proportion 
of patients (level change=−1.78; 95% CI −3.35 to –0.21; 
p=0.026) (online supplemental table S4).
DISCUSSION
In this study, we showed overall decreasing trends of 
sodium- containing medication prescribing in the UK 
after the 2013 BMJ publication highlighting the associa-
tion of use of these medications with cardiovascular risks. 
Significant reductions in the trends of sodium- containing 
medication prescribing were observed after the 2013 BMJ 
publication. The same change was not observed for the 
non- sodium- containing control formulations. The results 
from the THIN database and the PCA database were 
largely consistent with each other.
The 2013 publication might have had an impact on the 
prescribing practices of sodium- containing medications 
in the UK, which was reflected in the observed changes 
in the trends of prescribing between the prepublication 
period and the postpublication period. The same change 
was not observed for non- sodium- containing standard 
formulations. Comparing the prescribing trends from 
2014–2015 to 2016–2017, the guideline revision on excip-
ient labelling by the EMA in 2015 might have induced a 
further decline in the prescribing of sodium- containing 
drugs in addition to the impact of the 2013 BMJ publica-
tion. Comparing the results from the THIN database and 
the PCA database, the prescription rates from the THIN 
data were generally higher than from the PCA data. This 
observation could be attributed to two methodological 
differences in data analysis. First, using the patient- level 
data available in the THIN database, we excluded patients 
aged under 18 years, who are less likely to receive chronic 
treatment with the study medications while such informa-
tion was not available in the PCA database; second, data 
on GI motility agents were only analysed from the THIN 
database but not from the PCA database due to unclear 
product names of certain medicinal products from this 
drug class in the PCA database.
We found the decreased prescriptions of sodium- 
containing medications were not related to gender, while 
age might be an influential factor. We found there was 
a significant change in slope after the publication for 
patients over 45 years old, most likely due to the high 
cardiovascular risks in patients over 45 years.15 Interest-
ingly, the extent of reduction in prescribing did not simply 
increase in older age groups. The decline in prescribing 
slope was the highest in patients aged between 65 and 
74 years, with a 0.54% reduction in monthly prescribing 
of the sodium- containing medications. The percentage 
decreases in slope were 0.30% and 0.19% in the patients 
between 75–84 years old and over 85 years old, respec-
tively. As the swallowing impairment increases with old 
age, more older patients have dysphagia related to other 
diseases like stroke, Parkinson’s disease, dementia or 
cancer.16 17 Thus, switching of the effervescent, dispersible 
Figure 3 Prescribing trends of sodium- containing medications and control medications from 2009 to 2018, Prescription Cost 
Analysis data; (A) sodium, prescribing rate; (B) control, prescribing rate; (C) sodium, by regions; and (D) control, by regions.
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formulations to the non- sodium standard formulations 
might be less appropriate despite the higher cardiovas-
cular risks.
Across the UK, the prescribing practices in England, 
Scotland and Wales have changed to different extents, 
which might be impacted by the 2013 publication. The 
changes in prescribing trends were significant in England 
and Scotland, where the trends changed from a plateau 
before the publication to reduction of 7% annually 
after the publication. In Wales, the decreasing trends in 
sodium- containing medication prescribing pre- existed 
during the prepublication period and the change in the 
prescription rate was not significant after the 2013 publi-
cation. The driving force for these differential changes 
in prescribing trends is unclear, especially in absence of 
change in guidelines.18 19 A number of previous studies 
also reported intraregional differences in the prescribing 
of various medications.18 19 The prescribing rates in Scot-
land were higher than in England regardless of the publi-
cation impact. This could be attributable to differences 
between NHS prescription charges across regions in the 
UK, where prescription charges have been abolished in 
Scotland but not in England.20 Therefore, prescription- 
only medications are preferable compared with over- the- 
counter medications for patients in Scotland due to lower 
personal cost, especially when the medications are used 
long term.21 Notably, the prescription rate was the lowest 
in Wales despite the free prescriptions in this region.20 
The lower prescription rates could be due to the relatively 
lower chronic disease burden in this region.22 The rela-
tively low prescribing rates of other drugs in Wales than 
in England have been reported by previous studies.23 
In addition, national prescribing indicators were set in 
Wales to promote rational prescribing in certain clin-
ical areas.24 One of the aims of the national prescribing 
indicators published over the study period was to reduce 
the prescribing of non- steroidal anti- inflammatory drugs, 
which are the major component of sodium- containing 
drugs.24
The prescribing trends for medications of different 
therapeutic classes varied during the prepublication 
and postpublication periods. Analgesics were the most 
commonly prescribed sodium- containing medications 
while the prescribing was not changed after the publica-
tion. The prescribing rate of analgesics started to decrease 
during the prepublication period as initial concerns 
regarding associations with higher blood pressure of 
effervescent paracetamol tablets emerged in 2006 and 
were echoed in 2008 and 2009.25–27 Some practitioners 
might therefore have adopted a more cautious attitude 
towards prescribing effervescent paracetamol earlier 
than to other sodium- containing formulations. The 2013 
publication confirmed the association with cardiovascular 
adverse events of the medications. Calcium supplements 
and oral corticosteroids are the other two major classes 
of sodium- containing medications that may have been 
affected by the publication. The prescribing of both medi-
cation classes declined significantly since the publication. 
Apart from the impact from the BMJ publication, the 
changes in trends were possibly associated with other 
evidence updates over the study period. For example, the 
meta- analyses in 2012 and 2014 confirmed that calcium 
was not effective for the prevention of bone fractures,28 29 
which could have led to the overall reduction in calcium 
supplement prescribing. Two studies also reported a 
declining trend in prevalence of oral corticosteroid use in 
the UK and France from 2013 to 2014.30 31 Therefore, the 
observed trend changes could be the summation of the 
effects from the publication and other evidence changes 
over the study period.
Strengths and limitations
To the best of our knowledge, this is the first study eval-
uating recent trends for the prescribing of medications 
of sodium- containing, dispersible, effervescent or soluble 
formulations. Our analyses involved both the aggregate- 
level data for whole nations and the patient- level data 
from the THIN database, and we have shown the consis-
tency in results when measured in different parameters 
and from different databases. We have been able to assess 
the impacts of the 2013 BMJ publication on different 
regions in the UK, on medications from different thera-
peutic classes and different patient demographic groups.
However, there are limitations to our study. Our data 
sources were limited to the prescribing information in 
primary care and we were unable to evaluate the impact 
of the publication on prescribing practice in secondary 
care. Although we conducted the analysis on patient- 
level data, certain clinical characteristics of the patients, 
such as comorbidities and exposure time of the sodium- 
containing medications, were not included. We were 
not able to explore the factors other than age and sex, 
which might be associated with medication prescription 
or discontinuation as suggested by other previous publi-
cations.9 10 Furthermore, we were not able to include all 
dispersible, effervescent or soluble formulations available 
on prescription. As we aimed to investigate the impact 
of the publication, we included all equivalent formula-
tions to the drugs included in the original publication.3 
Although we used the pseudo- randomised ITSA with a 
control series included, we were still not able to establish 
the causal relationship between the intervention and the 
observed changes, the effect of other interventions or 
evidence changes during the analysis time period cannot 
be ruled out. We have conducted a number of multiple 
repeated analyses on different patient groups and medi-
cation classes, which could potentially introduce multi-
plicity issues with inflated statistical error rates. Results 
from the stratified statistical tests should be interpreted 
with caution.
CONCLUSION
In conclusion, the prescribing trend of sodium- 
containing, dispersible, effervescent or soluble medica-
tions has reduced significantly after the BMJ publication 
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Open access 
in 2013 highlighting associations between high sodium- 
containing medications and cardiovascular risks. The 
reduction was significant in patients aged over 45 years 
old. Across different regions in the UK, England and Scot-
land were affected by the publication the most. Changes 
in the prescribing trends for medications of different 
therapeutic classes were observed with variations, possibly 
due to other evidence changes during the study period. 
Further studies are warranted to investigate the factors 
that may drive the discontinuation/switching of the 
medications and the long- term health effects associated 
with medication discontinuation or switching.
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Table S1. Search criteria for sodium-containing medications from PCA databases 1 
Analgesics 
Co-codamol 500mg/8mg effervescent tablet 
  500mg/30mg effervescent tablet 
Paracetamol 500mg soluble tablet 
  120mg soluble tablet 
Ibuprofen 200mg soluble tablet 
Aspirin 300mg dispersible tablet 
Aspirin+metoclopramide No equivalent found 
Calcium supplements 
Calcium 1000mg(1g) effervescent tablet 
Calcium carbonate 1.25g effervescent tablet 








Histamine-2 receptor antagonists 
Ranitidine 150mg effervescent tablet 
  300mg effervescent tablet 
Zinc supplements 
Zinc sulphate 125mg effervescent tablet 
  220mg effervescent tablet 
Phosphate supplements 
Phosphate supplement 
(oral) effervescent tablet 
Phosphate Sandoz tablet 
Vitamin supplements 
Ascorbic acid 1g effervescent tablet 
Steroids 
Prednisone 5mg soluble tablet 
Betamethasone 500mcg soluble tablet 
2 
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Table S2. Search criteria for sodium-containing medications from THIN databases 
Drug code Generic name Formulation Strength Units 
Analgesics         
59452979 Co-codamol 30mg/500mg effervescent tablets                                                                              effervescent tablets                                                                                mg+mg                                             
93819990 Co-codamol 30mg/500mg effervescent tablets                                                                              effervescent tablets                                                                                mg+mg                                             
92377990 Co-codamol 8mg/500mg effervescent tablets                                                                               dispersible tablets                               8+500                                mg+mg                      
92417990 Co-codamol 30mg/500mg effervescent tablets                                                                              effervescent tablets                                                                                mg+mg                                             
94284990 Co-codamol 30mg/500mg effervescent tablets                                                                              effervescent tablets                                                                                mg+mg                                             
94827997 Co-codamol 30mg/500mg effervescent tablets                                                                              effervescent tablets                              500+30                                mg+mg                     
86582998 Co-codamol 30mg/500mg effervescent tablets                                                                              effervescent tablets                              30 + 500                                
mg + 
mg            
95671979 Co-codamol 30mg/500mg effervescent tablets                                                                              effervescent tablets                              500+30                                mg+mg                     
95673979 Co-codamol 30mg/500mg effervescent tablets                                                                              effervescent tablets                                                                                mg+mg                                             
95678979 Co-codamol 8mg/500mg effervescent tablets                                                                               dispersible tablets                               8+500                                mg+mg                      
95682979 Co-codamol 8mg/500mg effervescent tablets                                                                               dispersible tablets                               8+500                                mg+mg                      
95684979 Co-codamol 8mg/500mg effervescent tablets                                                                               dispersible tablets                               8+500                                mg+mg                      
88880998 Co-codamol 30mg/500mg effervescent tablets                                                                              effervescent tablets                                                                                mg+mg                                             
95450998 Co-codamol 8mg/500mg effervescent tablets                                                                               soluble tablets                                                                                                    
95464996 Co-codamol 30mg/500mg effervescent tablets                                                                              effervescent tablets                                                                                mg+mg                                             
95465997 Co-codamol 8mg/500mg effervescent tablets                                                                               dispersible tablets                               8+500                                mg+mg                      
96753997 Co-codamol 8mg/500mg effervescent tablets                                                                               dispersible tablets                               8+500                                mg+mg                      
97582998 Co-codamol 8mg/500mg effervescent tablets                                                                               dispersible tablets                                                                                                    
87547998 Co-codamol 30mg/500mg effervescent tablets                                                                              effervescent tablets                              30 + 500                                
mg + 
mg            
95206990 Co-codamol 30mg/500mg effervescent tablets                                                                              effervescent tablets                                                                                mg+mg                                             
92780990 Co-codamol 30mg/500mg effervescent tablets                                                                              effervescent tablets                                                                                mg+mg                                             
91123997 Co-codamol 30mg/500mg effervescent tablets                                                                              effervescent tablets                                                                                mg+mg                                             
94489990 Co-codamol 8mg/500mg effervescent tablets                                                                               dispersible tablets                               8+500                                mg+mg                      
93259998 Co-codamol 30mg/500mg effervescent tablets                                                                              effervescent tablets                              500 + 30                                mg +
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mg                                           
94470990 Co-codamol 8mg/500mg effervescent tablets                                                                               dispersible tablets                               8+500                                mg+mg                      
96616997 Co-codamol 8mg/500mg effervescent tablets                                                                               dispersible tablets                               8+500                                mg+mg                      
97071990 Co-codamol 8mg/500mg effervescent tablets                                                                               dispersible tablets                               8+500                                mg+mg                      
93342992 Co-codamol 30mg/500mg effervescent tablets                                                                              effervescent tablets                                                                                mg+mg                                             
97207989 Co-codamol 8mg/500mg effervescent tablets                                                                               dispersible tablets                               8+500                                mg+mg                      
94157990 Co-codamol 8mg/500mg effervescent tablets                                                                               dispersible tablets                               8+500                                mg+mg                      
95609990 Co-codamol 30mg/500mg effervescent tablets                                                                              effervescent tablets                                                                                mg+mg                                             
96304990 Co-codamol 8mg/500mg effervescent tablets                                                                               dispersible tablets                               8+500                                mg+mg                      
97876990 Co-codamol 8mg/500mg effervescent tablets                                                                               dispersible tablets                               8+500                                mg+mg                      
97984990 Co-codamol 8mg/500mg effervescent tablets                                                                               dispersible tablets                               8+500                                mg+mg                      
99674990 Co-codamol 8mg/500mg effervescent tablets                                                                               dispersible tablets                               8+500                                mg+mg                      
52678979 Paracetamol 500mg effervescent tablets                                                                                  soluble tablets                                   500 mg                                                
82980998 Paracetamol 500mg soluble tablets                                                                                       soluble tablets                                   500 mg                                                
21286978 Paracetamol 500mg effervescent tablets                                                                                  effervescent tablets                              500 mg                                                
93945992 Paracetamol 500mg effervescent tablets                                                                                  soluble tablets                                   500 mg                                                
95576990 Paracetamol 500mg effervescent tablets                                                                                  soluble tablets                                   500 mg                                                
95468998 Paracetamol 500mg effervescent tablets                                                                                  soluble tablets                                   500 mg                                                
94488990 Paracetamol 500mg effervescent tablets                                                                                  soluble tablets                                   500 mg                                                
95030990 Paracetamol 500mg effervescent tablets                                                                                  soluble tablets                                   500 mg                                                
98467998 Paracetamol 500mg soluble tablets                                                                                       soluble tablets                                   500 mg                                                
99476989 Paracetamol 500mg effervescent tablets                                                                                  soluble tablets                                   500 mg                                                
95440990 Paracetamol 500mg effervescent tablets                                                                                  soluble tablets                                   500 mg                                                
95608990 Paracetamol 500mg effervescent tablets                                                                                  effervescent tablets                              500 mg                                                
97858992 Paracetamol 500mg effervescent tablets                                                                                  soluble tablets                                   500 mg                                                
97741997 Paracetamol 120mg soluble tablets                                                                                       soluble tablets                                   120 mg                                                
97744998 Paracetamol 120mg soluble tablets sugar free                                                                            soluble tablets                                   120 mg                                                
81659998 Ibuprofen 200mg effervescent tablets                                                                                                                                                                                                           
96129990 Aspirin 300mg dispersible tablets                                                                                       dispersible tablets                               300 mg                                                
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94709997 Aspirin 300mg effervescent tablets sugar free                                                                           effervescent tablets                              300 mg                                                
90377998 Aspirin 300mg effervescent tablets sugar free                                                                                                                             300 mg                                                
91961979 Aspirin 300mg dispersible tablets                                                                                       dispersible tablets                               300 mg                                                
91962979 Aspirin 300mg dispersible tablets                                                                                       dispersible tablets                               300 mg                                                
91963979 Aspirin 300mg dispersible tablets                                                                                       dispersible tablets                               300 mg                                                
95911992 Aspirin 300mg dispersible tablets                                                                                       dispersible tablets                               300 mg                                                
97918989 Aspirin 300mg dispersible tablets                                                                                       dispersible tablets                               300 mg                                                
99283989 Aspirin 300mg dispersible tablets                                                                                       dispersible tablets                               300 mg                                                
99807989 Aspirin 300mg dispersible tablets                                                                                       dispersible tablets                               300 mg                                                
99808989 Aspirin 300mg dispersible tablets                                                                                       dispersible tablets                               300 mg                                                
99810989 Aspirin 300mg dispersible tablets                                                                                       soluble tablets                                   300 mg                                                
94513997 Aspirin 300mg effervescent tablets                                                                                      effervescent tablets                              300 mg                                                
97400998 Aspirin 300mg dispersible tablets                                                                                       dispersible tablets                               300 mg                                                
93368998 Aspirin 300mg dispersible tablets                                                                                       dispersible tablets                               300 mg                                                
96566989 Aspirin 300mg dispersible tablets                                                                                       dispersible tablets                               300 mg                                                
98419997 Aspirin 300mg dispersible tablets                                                                                       dispersible tablets                               300 mg                                                
96414990 Aspirin 300mg dispersible tablets                                                                                       dispersible tablets                               300 mg                                                
94589997 Aspirin 300mg effervescent tablets                                                                                      effervescent tablets                              300 mg                                                
98142989 Aspirin 300mg dispersible tablets                                                                                       soluble tablets                                   300 mg                                                
95351990 Aspirin 300mg dispersible tablets                                                                                       dispersible tablets                               300 mg                                                
97974989 Aspirin 300mg dispersible tablets                                                                                       dispersible tablets                               300 mg                                                
98592988 Aspirin 300mg dispersible tablets                                                                                       dispersible tablets                               300 mg                                                
98280998 Aspirin & metoclopramide 450mg+5mg effervescent tablets                                                                 effervescent tablets                              5 + 450                               
mg + 
mg             
99422998 Aspirin & metoclopramide 325mg+5mg effervescent tablets                                                                 effervescent tablets                              5 + 325                               
mg + 
mg             
          
Calcium 
supplements         
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99158997 
Calcium lactate gluconate 2.263g / Calcium carbonate 1.75g effervescent 
tablets sugar free                               effervescent tablets                                                                                mg                       
96896997 
Calcium lactate gluconate 2.263g / Calcium carbonate 1.75g effervescent 
tablets sugar free                               effervescent tablets                              1000 mg                                                
83457998 
Calcium lactate gluconate 2.263g / Calcium carbonate 1.75g effervescent 
tablets sugar free                               effervescent tablets                                                                                mg                       
82967998 
Calcium lactate gluconate with calcium carbonate and colecalciferol 600mg 
calcium with 400iu effervescent tablets        effervescent tablets                                                                                                   
84286998 Colecalciferol 400unit / Calcium carbonate 1.5g effervescent tablets                                                    soluble tablets                     1.5+10                                            g+mcg                     
92136979 Calcium carbonate 1.25g effervescent tablets sugar free                                                                 effervescent tablets                              500 mg                                                
93613998 Calcium carbonate 1.25g effervescent tablets sugar free                                                                 effervescent tablets                              500 mg                                                
93614998 Calcium carbonate 1.25g effervescent tablets sugar free                                                                 effervescent tablets                              1.25 g                                                 
85977998 Calcium carbonate 1.25g effervescent tablets sugar free                                                                 effervescent tablets                              1.25 g                                                 
97218998 Calcium gluconate 1g effervescent tablets                                                                               effervescent tablets                              1 g                                                 
97008992 Calcium carbonate 1.25g effervescent tablets sugar free                                                                 effervescent tablets                              500 mg                                                
89439998 
Colecalciferol 440unit / Calcium carbonate 1.25g effervescent granules 
sachets                                           granules                                          
500 + 
440                            mg + iu                                           
96959996 
Colecalciferol 440unit / Calcium carbonate 1.25g effervescent granules 
sachets                                           granules                                          1.25+440                                      g+iu                
          
Histamine-2 
receptor 
antagonists         
94763996 Ranitidine 150mg effervescent tablets                                                                                   effervescent tablets                              150 mg                                                
94764996 Ranitidine 150mg dispersible tablets                                                                                    dispersible tablets                               150 mg                                                
95583990 Ranitidine 300mg effervescent tablets                                                                                   effervescent tablets                              300 mg                                                
95889990 Ranitidine 300mg effervescent tablets                                                                                   effervescent tablets                              300 mg                                                
95890990 Ranitidine 150mg effervescent tablets                                                                                   effervescent tablets                              150 mg                                                
95914990 Ranitidine 300mg effervescent tablets                                                                                   effervescent tablets                              300 mg                                                
95915990 Ranitidine 150mg effervescent tablets                                                                                   effervescent tablets                              150 mg                                                
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95812990 Ranitidine 150mg effervescent tablets                                                                                   effervescent tablets                              150 mg                                                
96947998 Ranitidine 300mg effervescent tablets                                                                                   effervescent tablets                              300 mg                                                
95332996 Ranitidine 300mg effervescent tablets                                                                                   effervescent tablets                              300 mg                                                
95332997 Ranitidine 150mg effervescent tablets                                                                                   effervescent tablets                              150 mg                                                
95333996 Ranitidine 150mg dispersible tablet                                                                                     dispersible tablets                               150 mg                                                
          
Zinc 
supplements         
98342992 Zinc sulphate 220 mg tab                                                                                                effervescent tablets                              220 mg                                                
98346992 Zinc sulfate 220mg effervescent tablets                                                                                 effervescent tablets                              220 mg                                                
95608998 Zinc sulfate monohydrate 125mg effervescent tablets sugar free                                                          effervescent tablets                         125 mg                                                
95611998 Zinc sulfate monohydrate 125mg effervescent tablets sugar free                                                          dispersible tablets                        200 mg                                                
64552979 Zinc sulfate 220mg effervescent tablets sugar free                                                                                                                                                                  
          
GI motility 
agents         
81919998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free                                                sugar free granules                       3.5 g/sachet                                          
81938998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free                                                sugar free granules                       3.5 g/sachet                                          
81959998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free                                                sugar free granules                       3.5 g/sachet                                          
60079979 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free                                                sugar free granules                       3.5 g/sachet                                          
60080979 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free                                                sugar free granules                       3.5 g/sachet                                          
60081979 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free                                                sugar free granules                       3.5 g/sachet                                          
82692998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free                                                sugar free granules                       3.5 g/sachet                                          
82693998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free                                                sugar free granules                       3.5 g/sachet                                          
54399979 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free                                                sugar free granules                       3.5 g/sachet                                          
89619979 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free                                                sugar free granules                       3.5 g/sachet                                          
82445998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free                                                sugar free granules                       3.5 g/sachet                                          
82446998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free                                                sugar free granules                       3.5 g/sachet                                          
86509979 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free                                                sugar free granules                       3.5 g/sachet                                          
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87282998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free                                                sugar free granules                       3.5 g/sachet                                          
92212998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free                                                sugar free powder                       3.5 g/sachet                                          
97408998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free                                                sugar free granules                       3.5 g/sachet                                          
97409998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free                                                sugar free granules                       3.5 g/sachet                                          
95346998 Ispaghula husk 3.5g effervescent granules sachets gluten free sugar free                                                sugar free granules                       3.5 g/sachet                                          
          
Phosphate 
supplements         
93810998 Sodium dihydrogen phosphate anhydrous 1.936g effervescent tablets                                                       soluble tablets                 16.1 mmol                                              
99245998 Sodium dihydrogen phosphate anhydrous 1.936g effervescent tablets                                                       soluble tablets                                                                               
          
Vitamin 
supplements         
73603978 Ascorbic acid 1g effervescent tablets                                                                                                                                                                                       
69994979 Ascorbic acid 1g effervescent tablets                                                                                                                                                                                       
69995979 Ascorbic acid 1g effervescent tablets                                                                                                                                                                                       
89303998 Ascorbic acid 1g effervescent tablets                                                                                                                  1 g                                                 
94600997 Ascorbic acid 1g effervescent tablets                                                                                   dispersible tablets                               1 g                                                 
94602998 Ascorbic acid 1g effervescent tablets                                                                                   dispersible tablets                               1 g                                                 
          
Steroids         
26124978 Prednisolone 5mg soluble tablets                                                                                        soluble tablets                                   5 mg                                                
51132978 Prednisolone 5mg soluble tablets                                                                                        soluble tablets                                   5 mg                                                
95487992 Prednisolone 5mg soluble tablets                                                                                        soluble tablets                                   5 mg                                                
91788990 Prednisolone 5mg soluble tablets                                                                                        soluble tablets                                   5 mg                                                
93075998 Prednisolone 5mg soluble tablets                                                                                        soluble tablets                                   5 mg                                                
96577990 Prednisolone 5mg soluble tablets                                                                                        soluble tablets                                   5 mg                                                
93368979 Prednisolone 5mg soluble tablets                                                                                        soluble tablets                                   5 mg                                                
93369979 Prednisolone 5mg soluble tablets                                                                                        soluble tablets                                   5 mg                                                
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93370979 Prednisolone 5mg soluble tablets                                                                                        soluble tablets                                   5 mg                                                
55590979 Betamethasone 500microgram soluble tablets sugar free                                                                   soluble tablets                                   500 mcg                                               
92861998 Betamethasone 500microgram soluble tablets sugar free                                                                   soluble tablets                                   500 mcg                                               
93647992 Betamethasone 500microgram soluble tablets sugar free                                                                   soluble tablets                                   500 mcg                                               
93435979 Betamethasone 500microgram soluble tablets sugar free                                                                   soluble tablets                                   500 mcg                                               
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Table S3. Sensitivity analysis 1: ITSA of monthly prescribing data on sodium-containing medications and control medications 30 months before 




Baseline slope  
(95% CI) 
Change in level  
(95% CI) 
P-value 
Change in slope 
 (95% CI) 
P-value 
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Table S4. Sensitivity analysis 2: ITSA of monthly prescribing data on sodium-containing medications and control medications between 2014-
2015 versus 2016-2017, THIN data. 
  Baseline level 
(95% CI) 
Baseline slope  
(95% CI) 
Change in level 
(95% CI) 
P-value 
Change in slope 
 (95% CI) 
P-value 
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